Trial Profile
Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2019
Price :
$35
*
At a glance
- Drugs Neramexane (Primary)
- Indications Congenital nystagmus
- Focus Therapeutic Use
- Sponsors Merz Pharmaceuticals GmbH
- 10 Jun 2014 New trial record
- 25 Nov 2009
- 18 May 2009